Hikma Pharmaceuticals (HIKL)

1,580.00p
   
  • Change Today:
    -0.17p
  • 52 Week High: 1,857.00
  • 52 Week Low: 1,195.00
  • Currency: UK Pounds
  • Shares Issued: 199.39m
  • Volume: 27,802
  • Market Cap: £3,150.28m

HIKL Overview

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma’s operations are in the United States, the Middle East and North Africa Region and Europe.

Key Personnel

CEO: Said Darwazah
Chairman: Victoria Hull
Deputy CEO: Khalid Nabilsi
Executive Vice Chairman: Mazen Darwazah
Independent Non-Executive Director: Cynthia Schwalm
Independent Non-Executive Director: Laura Balan Balan
Independent Non-Executive Director: Deneen Vojta
Independent Non-Executive Director: Tobias Hestler
Senior Independent Director: Douglas Hurt
Non-Executive Dir: Ali Al-Husry

Contact Details

Address: 10 Portman Square, London, United Kingdom, W1H 6AZ
Phone: +44 (0)20 7399 2760
Fax: +44 (0)20 7399 2761
Website: http://www.hikma.com

Listings

Overseas Listings: LSE:HIK
ISIN: GB00B0LCW083

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 5 minutes.

 

HIKL Market Data

Currency UK Pounds
Share Price 1,580.00p
Change Today -0.17p
% Change -1.06 %
52 Week High 1,857.00
52 Week Low 1,195.00
Volume 27,802
Shares Issued 199.39m
Market Cap £3,150.28m

Trades for 09-Sep-2026

Time Volume / Share Price
11:12 426 @ 1,580.00p
11:12 7 @ 1,580.00p
11:08 198 @ 1,581.00p
11:08 150 @ 1,581.00p
11:02 71 @ 1,581.00p

HIKL Key Personnel

CEO Said Darwazah
Chair Victoria Hull

Top of Page